Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration

Phase 1

• Conditions: Age-related Macular Degeneration
• Interventions: Dietary Supplement: placebo; Dietary Supplement: Lutein; Drug: Lutein and zeaxanthin

• Registration Number: NCT01048476
• Lead Sponsor: Peking University

Brief Summary

Lutein is one of oxygenated carotenoids. Over the past few years, there has been increased interest in evaluating the effect of lutein for optimizing eye health. A large number of epidemiological studies support the notion that the high intake dietary of lutein is strongly associated with a decreased relative risk of AMD.Moreover, findings from initial observational studies have now been followed by placebo-controlled intervention trials showing that dietary modification and supplementation with lutein result in increasing the macular pigment optical density, and may help to improve visual function in patients suffering from AMD.Currently, nutritional status and background information of lutein and zeaxanthin in Chinese population is lack. Little is known about the preventive and therapy benefits of lutein on visual function in the AMD populations. In particular, the effect on visual function of relatively certain doses of lutein and zeaxanthin is unknown. Therefore, the objective of the present study was to examine the effect of consuming different doses of lutein on MPOD and visual function in AMD.

Detailed Description

We aim to study the effect and the mechanism of lutein in the prevention and treatment for age-related macular degeneration (AMD). Using the cluster sampling method, baseline characteristics screening will be performed in Han nationality men and women in the suburban areas of Beijing, ranging in age from 50 to79 years. According to clinical diagnosis standard of AMD, AMD (n=120) and normal subjects (n=40) will be randomly selected to measure serum lutein and nutritional status, and evaluate the relationship between lutein and AMD. Each subject of AMD will be randomly assigned to 1 of 4 groups: Group low lutein (Group LL); Group high lutein (Group HL); Group lutein/zeaxanthin (Group LZ); and Group Placebo to participate in the randomized, double-blind, placebo-controlled, 1 year intervention study, respectively. Macular pigment optical density,related symptoms and multifocal electroretinogram (mfERG) will be measured at at weeks 0, 24 and 48, to compare their dynamic changes in response to supplements at baseline and each follow-up visit, observe time- and dose-response correlation of supplementation with lutein, assess the efficacy, dosage of lutein and/or zeaxanthin supplement.

Study Timeline

• Study Start: 2009-09
• Study First Submitted: 2010-01-12
• Study First Submitted QC: 2010-01-12
• Study First Posted: 2010-01-13
• Status Verified: 2012-03
• Last Update Submitted: 2012-03-15
• Last Update Posted: 2012-03-16
• Primary Completion: 2012-04
• Study Completion: 2012-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Patients with nonexudative AMD (either categories 2, 3 or 4 according to the AREDS criteria; in group 4 the eyes with no-advanced AMD will be included)
• Age between 50 and 90 years
• Able to understand and comply with the requirements of the trial
• Visual acuity > 0.4
• Subjects must agree to take only the nutritional supplement that is

Exclusion Criteria

• Currently enrolled in an ophthalmic clinical trial
• Eyes with concomitant macular or choroidal disorders other than AMD and with indefinite signs of AMD
• Eyes with a diagnosis of exudative AMD with active subretinal neovascularization (SRNV) or CNV lesions requiring laser photocoagulation in the study eye
• Subjects with significant ocular lens opacities causing vision decrease
• Subjects with amblyopia
• Subjects with optic nerve disease (neuropathy, atrophy, papilledema), unstable glaucoma as defined by intraocular pressures greater than 25 mm Hg, 3 or more glaucoma medications, C/D of 0.8 or greater and visual fields consistent with glaucoma; history of retina-vitreous surgery, degenerative myopia, active posterior intraocular inflammatory disease, chronic use of topical ocular steroid medications, vasoproliferative retinopathies (other than AMD), rhegmatogenous retinal detachment, and inherited macular dystrophies
• Subjects with demand type pacemakers or epilepsy
• Subjects with uncontrolled hypertension (defined as diastolic of 90 or greater and systolic of 150 or greater)
• Subjects with recent history (within the previous year) of cerebral vascular disease
• manifested with transient ischemic attacks (TIA's) or cerebral vascular accidents (CVA's)
• Subjects with a history of AIDS
• lutein supplementation within the last 3 months
• Subjects who have had intraocular surgery in trial eye within 3 months prior to enrolling in the trial
• Patients who are unwilling to adhere to visit examination schedules

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group Placebo	placebo	Dietary Supplement: Placebo, 0 mg Lutein
Group L10	Lutein	Dietary Supplement: 10mg Lutein; daily supplementation one year
Group L20	Lutein	Dietary Supplement: 20mg Lutein; daily supplementation one year
Active Comparator: Group LZ	Lutein and zeaxanthin	Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year

Primary Outcome Measures

Name	Time	Method
MPOD and multifocal electroretinograms	1 year

Secondary Outcome Measures

Name	Time	Method
the safety and efficacy of lutein in reducing the risk of the development of advanced AMD.	1 year

Trial Locations

Locations (1)

Peking university; 🇨🇳 Beijing, Beijing, China